I have to admit I missed the hype about Elizabeth Holmes, and only learned about her from the Wall Street Journal hit job that came out last week (link). It feels like I arrived to the party after the police has shut the fun down!
Holmes had been profiled in all the important places--no doubt many of her interviewers are feeling a bit red-faced. She dropped out of Stanford to start a company that sells a full range of diagnostic tests based on tiny drops of blood. There is purportedly an underlying algorithm behind this product, known as "Edison". I use the word purportedly because few outside the company have seen the algorithm. Theranos said that is a trade secret.
The company is a big hit among the investment community. It is currently valued at $9 billion. Within the medical community, reaction has ranged from skepticism to cautious optimism. The secrecy simply means no expert in the field can judge whether this is vaporware or not. The WSJ report rounds up a number of former employees who claim that Theranos is all sizzle and no substance.
***
Like others, I have no evidence on which to judge whether the purported Theranos technology works. The other allegation by WSJ is that the vast majority of the test results provided by Theranos came from traditional methods, and thus are no different from other existing providers. This shines the light on the issue of business ethics.
Imagine that I am starting NewCo. NewCo is marketing some new invention, say, a new chair design that is better for your back. In fact, the NewCo chair is not better than other ergonomic chairs in the market. However, the chair is not any worse either. It is simply a re-branded chair of one of the chairs already in the market. NewCo sells this chair at a lower price because it has venture-capital money to subsidize the cost. In short, consumers are getting the same product at a lower price while thinking that they are getting a better product.
One point of view is that if this is legal, it is okay. No one forces a consumer to buy this chair; nor does anyone force an investor to put money in NewCo.
But something doesn't feel right here. Just because something may not be illegal, should you do it?
While consumers are not harmed, there are potential losers in this game: (a) the other competitors who lose market share because NewCo is selling its chair below cost, and (b) the future investors who are left holding the bag after the original NewCo investors cash out their investment.
You can of course argue that consumers are losing because they are being deceived. This view says money is not the only consideration.
***
Looking for precedents in the marketplace, I find that our legal system has no consistency in how we deal with these situations.
Tap water is being re-branded and sold to consumers. This is considered legal.
By contrast, one isn't allowed to sell a sugar pill as medicine, even if the pill does no harm, and even if the sugar pill might yield a clinical benefit through the placebo effect.
However, one can sell nutritional supplements which do not have strong science behind them.
For me, these issues cannot be solved in the legal system. We need ethical standards.
***
Since the initial expose, the Journal has published a couple of updates on Theranos:
FDA comes knocking (link)
An interview with Elizabeth Holmes (link)
Walgreens rethinks its relationship with Theranos (link)
I do not know why but I feel that one cause of this confusion is rooted in using such terms as "business ethics". Just act ethically, if you have to go to a course on "business ethics" then everything is lost already. If you view it from this point of view the behavior of NewCo is just not ethical, full stop.
Posted by: Christian | 10/27/2015 at 04:54 AM
It seems surprising that they don't have data, as comparing tests with continuous outcomes is fairly straightforward. Also there are standardised tests of how well calibrated they are. They can produce a publication comparing their methods to existing methods without revealing very much at all about the device. So you have to wonder why?
Posted by: Ken | 10/27/2015 at 06:45 AM
Fresh off the press: employee of "cryotherapy" clinic died while having cryotherapy. Link. No science behind such treatment but customers believe it is safe and effective.
Posted by: junkcharts | 10/27/2015 at 09:45 AM
From NYTimes http://www.nytimes.com/2015/10/28/business/theranos-quality-control-was-questioned-by-fda.html?_r=0 for those who don't have access to WSJ.
Posted by: Ken | 10/27/2015 at 05:26 PM
Context is important here. Every chair can claim some advantages. Every snack product can brag about great taste. Puffery in such contexts is common. Both chair ergonomics and taste have subjective components. It's not unethical to have an informercial where two actual users claim your chair is the most comfortable they've ever used and their back doesn't hurt.
In the medical field, there are more stringent ethical and legal requirements since the field inherently involves issues of life and death.
Nutritional supplements by law have to state essentially that "nobody knows whether this works - certainly not the FDA".
Posted by: zbicyclist | 10/28/2015 at 10:38 AM
zbicyclist: Thanks for filling in the other side of the story. Ethics is a community standard. I don't think we will ever get consensus. There are certainly many products out in the market that pretend to have health benefits but don't actually have any science behind them. Consumers who purchase these products are fooled. They may even kill, as the cryotherapy case shows. I personally feel troubled by such cases. But the gray area is where there is bad science - and lord knows, it is easy to publish bad science, as is well-documented on other blogs, like Andrew Gelman's.
Christian: I agree that ethics don't have to have a business context. However, the existence of the profit motive is a driver of some unethical behaviors. I sometimes hear justification based on cost/benefit calculations.
Posted by: Kaiser | 10/28/2015 at 10:52 AM
NYTimes has an article http://www.nytimes.com/2015/10/30/business/the-narrative-frays-for-theranos-and-elizabeth-holmes.html?ref=business where several experts raise the same basic concern as I have. This is something that is easy to test, so why haven't they, and if they have why haven't the results been made public.
Posted by: Ken | 10/30/2015 at 04:37 PM